{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:56:55Z","timestamp":1773712615992,"version":"3.50.1"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0217303","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:31:17Z","timestamp":1559064677000},"page":"e0217303","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-237X","authenticated-orcid":true,"given":"Evgeniy","family":"Evdoshenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Shumilina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Davydovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Khachanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9823","authenticated-orcid":true,"given":"Nikolay","family":"Neofidov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Kalinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Popova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Dubchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Pozhidaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Volkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-5932","authenticated-orcid":true,"given":"Stella","family":"Sivertseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Prilenskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda","family":"Malkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Korobko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Vergunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Shchur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gleb","family":"Makshakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.30809\/phe.2.2016.5","article-title":"Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme \u20187 high-cost nosologies\u2019 on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients","volume":"4","author":"E. Evdoshenko","year":"2016","journal-title":"Pharmacoeconomics: theory and practice"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"R. Rudick","year":"2007","journal-title":"Annals of Neurology"},{"key":"ref3","unstructured":"\u0414\u0430\u0432\u044b\u0434\u043e\u0432\u0441\u043a\u0430\u044f \u041c.\u0412. \u041f\u043b\u0430\u043d \u0443\u043f\u0440\u0430\u0432\u043b\u0435\u043d\u0438\u044f \u0440\u0438\u0441\u043a\u0430\u043c\u0438 \u043f\u0440\u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043d\u0430\u0442\u0430\u043b\u0438\u0437\u0443\u043c\u0430\u0431\u043e\u043c. \u0416\u0443\u0440\u043d\u0430\u043b \u043d\u0435\u0432\u0440\u043e\u043b\u043e\u0433\u0438\u0438 \u0438 \u043f\u0441\u0438\u0445\u0438\u0430\u0442\u0440\u0438\u0438 \u0438\u043c. \u0421.\u0421. \u041a\u043e\u0440\u0441\u0430\u043a\u043e\u0432\u0430. 2011;111:2:105\u2013109"},{"issue":"8. Vyp. 2","key":"ref4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.17116\/jnevro20151158225-35","article-title":"A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis","volume":"115","author":"A. Boyko","year":"2015","journal-title":"Zhurnal nevrologii i psikhiatrii im"},{"issue":"10. Vyp. 2","key":"ref5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.17116\/jnevro201611610279-97","article-title":"Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab","volume":"116","author":"M. Davydovskaya","year":"2016","journal-title":"Zhurnal nevrologii i psikhiatrii im"},{"key":"ref6"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis","volume":"37","author":"A. Traboulsee","year":"2015","journal-title":"American Journal of Neuroradiology"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1352458517709619","article-title":"Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study","volume":"24","author":"L. Kappos","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"P. O\u2019Connor","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis","volume":"354","author":"C. Polman","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13760-014-0308-9","article-title":"Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program","volume":"114","author":"V. van Pesch","year":"2014","journal-title":"Acta Neurologica Belgica"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"H. Butzkueven","year":"2014","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"N. Schwab","year":"2016","journal-title":"Neurology\u2014Neuroimmunology Neuroinflammation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0217303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T23:41:55Z","timestamp":1608075715000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0217303"}},"subtitle":[],"editor":[{"given":"Aristeidis H.","family":"Katsanos","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0217303","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]}}}